Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XGN Stock Forecast 2026-2027
$3.08
Current Price
$74.08M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XGN Price Targets
+224.7%
To High Target of $10.00
+208.4%
To Median Target of $9.50
+127.3%
To Low Target of $7.00
XGN Price Momentum
+3.7%
1 Week Change
+10.8%
1 Month Change
-31.4%
1 Year Change
-49.3%
Year-to-Date Change
-74.8%
From 52W High of $12.23
+18.9%
From 52W Low of $2.59
📊 TOP ANALYST CALLS
Did XGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Exagen is one of their latest high-conviction picks.
Latest XGN Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, XGN has a bullish consensus with a median price target of $9.50 (ranging from $7.00 to $10.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $3.08, the median forecast implies a 208.4% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kyle Mikson at Canaccord Genuity, projecting a 224.7% upside. Conversely, the most conservative target is provided by Ross Osborn at Cantor Fitzgerald, suggesting a 127.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XGN Analyst Ratings
7
Buy
0
Hold
0
Sell
XGN Price Target Range
Low
$7.00
Average
$9.50
High
$10.00
Current: $3.08
Latest XGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2026 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $10.00 |
| Mar 11, 2026 | Keybanc | Paul Knight | Overweight | Maintains | $10.00 |
| Mar 11, 2026 | Craig-Hallum | John Wilkin | Buy | Maintains | $10.00 |
| Mar 10, 2026 | BTIG | Mark Massaro | Buy | Maintains | $9.00 |
| Feb 24, 2026 | TD Cowen | Dan Brennan | Buy | Maintains | $10.00 |
| Feb 17, 2026 | BTIG | Mark Massaro | Buy | Maintains | $10.00 |
| Jan 30, 2026 | B. Riley Securities | Anderson Schock | Buy | Reiterates | $8.00 |
| Nov 10, 2025 | BTIG | Mark Massaro | Buy | Maintains | $15.00 |
| Nov 5, 2025 | B. Riley Securities | Anderson Schock | Buy | Reiterates | $18.00 |
| Oct 27, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $15.00 |
| Oct 22, 2025 | BTIG | Mark Massaro | Buy | Maintains | $13.00 |
| Oct 14, 2025 | Keybanc | Paul Knight | Overweight | Maintains | $15.00 |
| Sep 11, 2025 | B. Riley Securities | Anderson Schock | Buy | Initiates | $15.00 |
| Jul 30, 2025 | Keybanc | Paul Knight | Overweight | Upgrade | $12.00 |
| Jul 30, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $11.00 |
| Jul 23, 2025 | Craig-Hallum | John Wilkin | Buy | Initiates | $12.00 |
| May 15, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $7.00 |
| May 13, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $8.00 |
| Jan 13, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $8.00 |
| Jan 3, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $7.00 |
Exagen Inc. (XGN) Competitors
The following stocks are similar to Exagen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Exagen Inc. (XGN) Financial Data
Valuation Metrics
Market Cap
$74.08M
Enterprise Value
$69.53M
P/E Ratio
N/A
PEG Ratio
-6.8x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
+21.8%
Gross Margin
+55.4%
Operating Margin
-29.9%
Net Margin
-30.0%
EPS Growth
+21.8%
Financial Health
Cash/Price Ratio
+43.5%
Current Ratio
3.5x
Debt/Equity
158.6x
ROE
-147.8%
ROA
-17.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Exagen Inc. (XGN) Business Model
About Exagen Inc.
What They Do
Provides autoimmune testing solutions for healthcare providers.
Business Model
Exagen Inc. generates revenue by designing, developing, and commercializing diagnostic tests for autoimmune diseases under the AVISE brand. The company targets healthcare providers, offering specialized testing products that aid in the diagnosis and monitoring of conditions like systemic lupus erythematosus and rheumatoid arthritis, thus enhancing patient care and enabling timely interventions.
Additional Information
Based in Carlsbad, California, Exagen Inc. is focused on increasing the adoption of its laboratory tests among rheumatologists while supporting clinical research through presentations at medical conferences. Its lead product, AVISE CTD, is crucial for differential diagnosis in patients with complex autoimmune conditions.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
209
CEO
Mr. John Aballi
Country
United States
IPO Year
N/A
Website
www.exagen.comExagen Inc. (XGN) Latest News & Analysis
Latest News
Quick Summary
Exagen Inc. (XGN) held its Q4 2025 earnings call, discussing financial performance and future outlook. Details on revenue, expenses, and strategic initiatives were shared.
Why It Matters
Exagen Inc.'s Q4 2025 earnings call provides insights into financial performance, future guidance, and market trends, impacting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Exagen Inc. reported record full-year revenue and over 11% growth in test volume, driven by new biomarkers and sales force expansion, for the year ending December 31, 2025.
Why It Matters
Exagen's record revenue and significant test volume growth signal strong market demand and effective sales strategies, indicating potential for continued financial performance and stock value increase.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Exagen Inc. (XGN) reported a quarterly loss of $0.20 per share, matching the Zacks Consensus Estimate, consistent with a loss of $0.20 per share from the previous year.
Why It Matters
Exagen Inc.'s quarterly loss meeting expectations indicates stability, potentially reassuring investors about management's performance and future earnings outlook.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Exagen Inc. (Nasdaq: XGN) will participate in the KeyBank Capital Markets Healthcare Forum on March 17, 2026, with investor meetings and a fireside chat at 3:00 p.m.
Why It Matters
Exagen's participation in key investor conferences signals engagement with the investment community, potentially influencing stock perception and attracting interest in its autoimmune testing products.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
1 month ago
Quick Summary
Exagen Inc. (Nasdaq: XGN) will announce its Q4 2025 financial results on March 10, 2026, before market open. A conference call will follow at 8:30 a.m. ET.
Why It Matters
Exagen Inc.'s upcoming earnings report could impact stock performance, influencing investor sentiment and market valuation based on financial results and management insights shared during the call.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Exagen Inc. (Nasdaq: XGN) reported preliminary unaudited financial results for Q4 and full year 2025, aligning with previous guidance.
Why It Matters
Exagen's preliminary results meeting guidance suggest stability in performance, reassuring investors about potential growth and reliability in their financial outlook.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XGN Stock
What is Exagen Inc.'s (XGN) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Exagen Inc. (XGN) has a median price target of $9.50. The highest price target is $10.00 and the lowest is $7.00.
Is XGN stock a good investment in 2026?
According to current analyst ratings, XGN has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XGN stock?
Wall Street analysts predict XGN stock could reach $9.50 in the next 12 months. This represents a 208.4% increase from the current price of $3.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Exagen Inc.'s business model?
Exagen Inc. generates revenue by designing, developing, and commercializing diagnostic tests for autoimmune diseases under the AVISE brand. The company targets healthcare providers, offering specialized testing products that aid in the diagnosis and monitoring of conditions like systemic lupus erythematosus and rheumatoid arthritis, thus enhancing patient care and enabling timely interventions.
What is the highest forecasted price for XGN Exagen Inc.?
The highest price target for XGN is $10.00 from Kyle Mikson at Canaccord Genuity, which represents a 224.7% increase from the current price of $3.08.
What is the lowest forecasted price for XGN Exagen Inc.?
The lowest price target for XGN is $7.00 from Ross Osborn at Cantor Fitzgerald, which represents a 127.3% increase from the current price of $3.08.
What is the overall XGN consensus from analysts for Exagen Inc.?
The overall analyst consensus for XGN is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.50.
How accurate are XGN stock price projections?
Stock price projections, including those for Exagen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 4:19 AM UTC